Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Rani Therapeutics Holdings, Inc. (RANI)

Rani Therapeutics adds Michelle Gilson to board, names her Audit Committee chair

Neutral Impact 2 of 5 leadership Written later

Rani Therapeutics Holdings appointed Michelle Gilson to its board of directors effective August 1, 2026, and named her chair of the Audit Committee. Gilson previously served as chief financial officer of Arcellx, Inc. until its acquisition by Gilead Sciences in April 2026, and the filing describes no change to the company's financial results or guidance.

Key points

  • Michelle Gilson appointed to the board on August 1, 2026, serving until the next annual meeting or until a successor is appointed
  • Gilson also appointed chair of the Audit Committee
  • Gilson was CFO of Arcellx, Inc. from May 2022 until Gilead Sciences acquired it in April 2026
  • Company will enter into its standard indemnification agreement with Gilson

The filing

CompanyRani Therapeutics Holdings, Inc. (RANI)
Form8-K, current report
Filed with the SECAug 4, 2026, 8:05 AM ET
Accession number0001193125-26-331594

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.